-
Mashup Score: 2
At the 2024 UCSF-UCLA PSMA Conference, Wolfgang Fendler emphasizes the transformative role of PSMA-PET imaging in managing castration-resistant prostate cancer (CRPC), showcasing its ability to reveal a more extensive disease burden and detect distant metastases in patients previously considered non-metastatic. Dr. Fendler highlights a multicenter trial that demonstrates PSMA-PET’s significant…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 2Role of PSMA PET in CRPC Patients "Presentation" - Wolfgang Fendler - 1 month(s) ago
At the 2024 UCSF-UCLA PSMA Conference, Wolfgang Fendler emphasizes the transformative role of PSMA-PET imaging in managing castration-resistant prostate cancer (CRPC), showcasing its ability to reveal a more extensive disease burden and detect distant metastases in patients previously considered non-metastatic. Dr. Fendler highlights a multicenter trial that demonstrates PSMA-PET’s significant…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
The role of PSMA PET in #CRPC patients. Presentation by Wolfgang Fendler, MD @DKTK_ emphasizing the transformative role of PSMA-PET imaging in managing CRPC, showcasing its ability to reveal a more extensive disease burden and detect distant metastases > https://t.co/iWJjm6oJG3 https://t.co/vTNzPQ9pHO
-
-
Mashup Score: 0Talazoparib Plus Enzalutamide Significantly Improves PFS in Patients With HRR mCRPC - 10 month(s) ago
Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0SNMMI 2023: PSMA PET Prognostic Value for Outcome of Pre-Chemotherapy Post-ARSI CRPC Patients: A Single Center Retrospective Analysis - 10 month(s) ago
SNMMI 2023, prostate cancer, Pre-Chemotherapy Post-ARSI, prostate-specific membrane antigen (PSMA), positron emission tomography (PET), castrate-resistant prostate cancer (CRPC), Biochemical progression, androgen deprivation therapy (ADT), ARSI, stereotactic body radiation therapy (SBRT).
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0Talazoparib Plus Enzalutamide Significantly Improves PFS in Patients With HRR mCRPC - 10 month(s) ago
Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Talazoparib Plus Enzalutamide Significantly Improves PFS in Patients With HRR mCRPC - 10 month(s) ago
Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Source: Oncology Nursing NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer - 11 month(s) ago
Using comprehensive plasma lipidomic profiling from men with metastatic castration-resistant prostate cancer (mCRPC), we have previously identified a poor-prognostic lipid profile associated with shorter overall survival (OS). In order to translate this biomarker into the clinic, these men must be identifiable via a clinically accessible, regulatory-compliant assay. A single regulatory-compliant…
Source: www.nature.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1HOME - Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy - 12 month(s) ago
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HOME - Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy - 1 year(s) ago
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0HOME - Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy - 1 year(s) ago
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy.
Source: event.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The role of PSMA PET in #CRPC patients. Presentation by Wolfgang Fendler, MD @DKTK_ emphasizing the transformative role of PSMA-PET imaging in managing CRPC, showcasing its ability to reveal a more extensive disease burden and detect distant metastases > https://t.co/iWJjm6oJG3 https://t.co/vTNzPQ9pHO